US 10519247
Targeting HER2 and HER3 with bispecific antibodies in cancerous cells
granted A61KA61K2039/505A61K31/517
Quick answer
US patent 10519247 (Targeting HER2 and HER3 with bispecific antibodies in cancerous cells) held by The Board of Regents of the University of Texas System expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The Board of Regents of the University of Texas System
- Grant date
- Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 12
- CPC classes
- A61K, A61K2039/505, A61K31/517, A61K39/39558, A61K45/06